ArticleJournal of molecular medicine (Berlin, Germany)2017
VPS52 induces apoptosis via cathepsin D in gastric cancer.
Article in Journal of molecular medicine (Berlin, Germany), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- GARP Complex in Golgi Physiology.Sub-cellular biochemistry · 2026Review
- Anticancer effect of piperine, a black pepper compound, regulating apoptosis mediated through extracellular vesicles and cathepsin D in acute leukemia.Scientific reports · 2025Article
- Investigating PPT2's role in ovarian cancer prognosis and immunotherapy outcomes.Journal of ovarian research · 2024Article
- Prognostic marker VPS72 could promote the malignant progression of prostate cancer.BMC cancer · 2024Article
- Article
- VPS72, a member of VPS protein family, can be used as a new prognostic marker for hepatocellular carcinoma.Immunity, inflammation and disease · 2023Article
- Role of GARP Vesicle Tethering Complex in Golgi Physiology.International journal of molecular sciences · 2023Review
- Lysosomal peptidases-intriguing roles in cancer progression and neurodegeneration.FEBS open bio · 2022Review
- Genetic Influence on Frequencies of Myeloid-Derived Cell Subpopulations in Mouse.Frontiers in immunology · 2021Article
- Cathepsins in the Pathophysiology of Mucopolysaccharidoses: New Perspectives for Therapy.Cells · 2020Review
- Exploration in the Mechanism of Kaempferol for the Treatment of Gastric Cancer Based on Network Pharmacology.BioMed research international · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vacuolar protein sorting (VPS) genes encode a class of proteins involved in vesicular trafficking. Growing evidence suggests that VPS proteins play roles in tumor biology. Vacuolar protein sorting 52 (VPS52) is involved in retrograde transport of endosomes, and its roles in cancers have not been explored. This study investigated the genetic alterations, protein changes, biological role, and molecular mechanism of VPS52 in gastric cancer. Loss of heterozygosity of VPS52 was detected in 52.9% (9/17) of gastric cancer samples. Twenty-five percent (5/20) gastric cancer samples contained somatic stop-gain mutation of VPS52, two of which also had simultaneous loss of heterozygosity. Lack of VPS52 protein expression in gastric cancer tissue was found compared with pericancerous tissue and was significantly correlated with more advanced TNM staging and shorter 3-year overall survival. Overexpression of VPS52 significantly reduced viability and increased apoptosis in gastric cancer cells in vitro and reduced tumor volume and tumor weight in xenograft model in vivo. Activation of the cathepsin D/Bax/cytochrome C/caspase 9/caspase 3 pathway was detected in gastric cancer cells overexpressing VPS52. Collectively, VPS52 is a tumor suppressor gene in gastric cancer and could be used as a biomarker. VPS52 adenovirus could be a novel anti-tumor reagent for future gene therapy. KEY MESSAGES: Loss of heterozygosity and stop-gain mutation of VPS52 were found in gastric cancer. Negative expression of VPS52 significantly correlated with poor prognosis. VPS52 inhibited viability and induced apoptosis of gastric cancer cells in vitro. VPS52 reduced tumor volume and tumor weight in vivo. VPS52 activated the apoptotic pathway through cathepsin D in gastric cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.